Risk of infection associated with anti-TNF-α therapy

References

• Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72:3666–3670.
   PubMed Web of Science ®Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729–733.
   PubMed Web of Science ®Google Scholar
• Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev. 2014;25:453–472.
   PubMed Web of Science ®Google Scholar
• Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501.
   PubMed Web of Science ®Google Scholar
• Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell Signal. 2012;24:1297–1305.
   PubMed Web of Science ®Google Scholar
• Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 2008;58:S92–S101.
   PubMedGoogle Scholar
• Takashiba S, Van Dyke TE, Amar S, et al. Differentiation of monocytes to macrophages primes cells for lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear factor kappaB. Infect Immun. 1999;67:5573–5578.
   PubMed Web of Science ®Google Scholar
• Mackay F, Loetscher H, Stueber D, et al. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med. 1993;177:1277–1286.
   PubMed Web of Science ®Google Scholar
• Gibbs LS, Lai L, Malik AB. Tumor necrosis factor enhances the neutrophil-dependent increase in endothelial permeability. J Cell Physiol. 1990;145:496–500.
   PubMed Web of Science ®Google Scholar
• Rothe J, Lesslauer W, Lotscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364:798–802.
   PubMed Web of Science ®Google Scholar
• Wong GH, Goeddel DV. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature. 1986;323:819–822.
   PubMed Web of Science ®Google Scholar
• O’Brien DP, Briles DE, Szalai AJ, et al. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun. 1999;67:595–601.
   PubMed Web of Science ®Google Scholar
• Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002;168:4620–4627.
   PubMed Web of Science ®Google Scholar
• Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol. 2017;17:691–702.
   PubMed Web of Science ®Google Scholar
• Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 1999;162:3504–3511.
   PubMed Web of Science ®Google Scholar
• Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity. 2008;29:283–294.
   PubMed Web of Science ®Google Scholar
• Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986;322:547–549.
   PubMed Web of Science ®Google Scholar
• Brennan FM, Field M, Chu CQ, et al. Cytokine expression in rheumatoid arthritis. Br J Rheumatol. 1991;30(Suppl 1):76–80.
   PubMedGoogle Scholar
• Wong M, Ziring D, Korin Y, et al. TNF-alpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126:121–136.
   PubMed Web of Science ®Google Scholar
• Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118:3537–3545.
   PubMed Web of Science ®Google Scholar
• Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329–342.
   PubMed Web of Science ®Google Scholar
• Perrier C, de Hertogh G, Cremer J, et al. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis. 2013;19:246–253.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;175:2721–2729.
   PubMed Web of Science ®Google Scholar
• Kelly G, Sweeney CM, Tobin AM, et al. Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol. 2014;53:1186–1196.
   PubMed Web of Science ®Google Scholar
• Steffen M, Petersen J, Oldigs M, et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol. 1993;91:939–949.
   PubMed Web of Science ®Google Scholar
• Duzgun N, Ayaslioglu E, Tutkak H, et al. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet’s disease. Rheumatol Int. 2005;25:1–5.
   PubMed Web of Science ®Google Scholar
• Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2:244–247.
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105–1110.
   PubMed Web of Science ®Google Scholar
• van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129–135.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 study group. N Engl J Med. 1997;337:1029–1035.
   PubMed Web of Science ®Google Scholar
• Valle E, Gross M, Bickston SJ. Infliximab. Expert Opin Pharmacother. 2001;2:1015–1025.
   PubMedGoogle Scholar
• Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs. 1999;57:945–966.
   PubMed Web of Science ®Google Scholar
• Berns M, Hommes DW. Anti-TNF-alpha therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opin Investig Drugs. 2016;25:129–143.
   PubMed Web of Science ®Google Scholar
• Cohen S, Kay J. Biosimilars: implications for rheumatoid arthritis therapy. Curr Opin Rheumatol. 2017;29:260–268.
   PubMed Web of Science ®Google Scholar
• Oikonomopoulos A, van Deen WK, Hommes DW. Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? Curr Drug Targets. 2013;14:1421–1432.
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn’s disease and rheumatoid arthritis. Drugs. 2005;65:2179–2208.
   PubMed Web of Science ®Google Scholar
• Robinson DM, Keating GM. Infliximab: in ankylosing spondylitis. Drugs. 2005;65: 1283–1291. discussion 1292-1284.
   PubMedGoogle Scholar
• Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc). 2011;47:277–288.
   PubMed Web of Science ®Google Scholar
• Campas-Moya C. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Drugs Today (Barc). 2010;46:13–22.
   PubMed Web of Science ®Google Scholar
• Ueda N, Tsukamoto H, Mitoma H, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor alpha. Inflamm Bowel Dis. 2013;19:1224–1231.
   PubMed Web of Science ®Google Scholar
• Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014;28(Suppl 1):S15–23.
   PubMed Web of Science ®Google Scholar
• Marotte H, Cimaz R. Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther. 2014;14:569–572.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248–1257.
   PubMed Web of Science ®Google Scholar
• Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: A metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42:2229–2237.
   PubMed Web of Science ®Google Scholar
• Liao H, Zhong Z, Liu Z, et al. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis. 2017;20:161–168.
   PubMed Web of Science ®Google Scholar
• Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258–265.
   PubMed Web of Science ®Google Scholar
• Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014;127:1208–1232.
   PubMed Web of Science ®Google Scholar
• Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136–1145.
   PubMed Web of Science ®Google Scholar
• Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2011;63:1479–1485.
   PubMed Web of Science ®Google Scholar
• Wang S, He Q, Shuai Z. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Clin Rheumatol. 2018;37:439–450.
   PubMed Web of Science ®Google Scholar
• Fouque-Aubert A, Jette-Paulin L, Combescure C, et al. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis. 2010;69:1756–1761.
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035–1050.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385–1397 e1310.
   PubMed Web of Science ®Google Scholar
• Zhang D, Xiong B, Li X, et al. Meta-analysis: serious adverse events in Crohn’s disease patients treated with TNF-alpha inhibitors. Hepatogastroenterology. 2013;60:1333–1342.
   PubMedGoogle Scholar
• Westerouen van Meeteren MJ, Hayee B, Inderson A, et al. Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis. J Crohns Colitis. 2017;11:1146–1151.
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: fcfusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–259.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478–486.
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–1104.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15:11–34.
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794.
   Google Scholar
• Xu Z, Xu P, Fan W, et al. Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials. Exp Ther Med. 2017;14:3491–3500.
   PubMed Web of Science ®Google Scholar
• Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268–1276.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015;74:2107–2116.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:990–997.
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306:2331–2339.
   PubMed Web of Science ®Google Scholar
• Pérez-Sola MJ, Torre-Cisneros J, Perez-Zafrilla B, et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 2011;137:533–540.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66:1339–1344.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12:225–229.
   PubMed Web of Science ®Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124–131.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol. 2010;37:928–931.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Tang B, Lu L, et al. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis. 2014;17:291–298.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72:37–42.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986–1992.
   PubMed Web of Science ®Google Scholar
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884–1894.
   PubMed Web of Science ®Google Scholar
• Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43:717–722.
   PubMed Web of Science ®Google Scholar
• Kim EM, Uhm WS, Bae SC, et al. Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol. 2011;38:2218–2223.
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122–2127.
   PubMed Web of Science ®Google Scholar
• Goletti D, Petrone L, Ippolito G, et al. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther. 2018;16:501–512.
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70:616–623.
   PubMed Web of Science ®Google Scholar
• Pena-Sagredo JL, Hernandez MV, Fernández-Llanio N, et al. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol. 2008;26:854–859.
   PubMed Web of Science ®Google Scholar
• Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48:319–324.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261–1265.
   PubMed Web of Science ®Google Scholar
• Ali T, Chakraburtty A, Mahmood S, et al. Risk of nocardial infections with anti-tumor necrosis factor therapy. Am J Med Sci. 2013;346:166–168.
   PubMed Web of Science ®Google Scholar
• Fabre S, Gibert C, Lechiche C, et al. Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. J Rheumatol. 2005;32:2432–2433.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yin G, Tan C, et al. Cat scratch disease during infliximab therapy: a case report and literature review. Rheumatol Int. 2015;35:911–913.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887–895.
   PubMed Web of Science ®Google Scholar
• Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the british society for rheumatology biologics register. Ann Rheum Dis. 2013;72:229–234.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301:737–744.
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010;69:1751–1755.
   PubMed Web of Science ®Google Scholar
• Serac G, Tubach F, Mariette X, et al. Risk of herpes zoster in patients receiving anti-TNF-alpha in the prospective French RATIO registry. J Invest Dermatol. 2012;132:726–729.
   PubMed Web of Science ®Google Scholar
• Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut. 2004;53:1363–1365.
   PubMed Web of Science ®Google Scholar
• Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol. 2003;30:1624–1625.
   PubMed Web of Science ®Google Scholar
• Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686–687.
   PubMed Web of Science ®Google Scholar
• Pérez-Álvarez R, Díaz-Lagares C, García-Hernández F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359–371.
   PubMed Web of Science ®Google Scholar
• Pauly MP, Tucker LY, Szpakowski JL, et al. Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. epub ahead of print. 2018 Apr 24.DOI:10.1016/j.cgh.2018.04.033.
   Google Scholar
• Brunasso AM, Puntoni M, Gulia A, et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011;50:1700–1711.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Selective TNF-α inhibitor-induced injection site reactions. Expert Opin Drug Saf. 2013;12:187–193.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Sandborn WJ, Colombel JF, et al. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111:1806–1815.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis. 2014;73:1942–1948.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70:1914–1920.
   PubMed Web of Science ®Google Scholar
• Momohara S, Kawakami K, Iwamoto T, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21:469–475.
   PubMed Web of Science ®Google Scholar
• Hayata K, Kanbe K, Chiba J, et al. Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab. Int J Rheum Dis. 2011;14:31–36.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56:2896–2904.
   PubMed Web of Science ®Google Scholar
• Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum. 2009;61:300–304.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522–528.
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418–426.
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49:1215–1228.
   PubMed Web of Science ®Google Scholar
• MacEwan DJ. TNF ligands and receptors: a matter of life and death. Br J Pharmacol. 2002;135:855–875.
   PubMed Web of Science ®Google Scholar
• Rutherford AI, Subesinghe S, Hyrich KL, et al. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77:905–910.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Burmester GR, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016;388:2763–2774.
   PubMed Web of Science ®Google Scholar
• Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14:503–509.
   PubMed Web of Science ®Google Scholar
• Park DI, Hisamatsu T, Chen M, et al. Asian organization for crohn’s and colitis and asia pacific association of gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intest Res. 2018;16:4–16.
   PubMed Web of Science ®Google Scholar
• Abreu C, Sarmento A, Magro F. Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients. Dig Liver Dis. 2017;49:1289–1297.
   PubMedGoogle Scholar
• Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). Clin Microbiol Infect. 2018;24(Suppl 2):S10–S20.
   PubMed Web of Science ®Google Scholar
• Dominguez J, Latorre I, Santin M. Diagnosis and therapeutic approach of latent tuberculosis infection. Enferm Infecc Microbiol Clin. 2018;36:302–311.
   PubMed Web of Science ®Google Scholar
• Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356:1099–1104.
   PubMed Web of Science ®Google Scholar
• Muñoz L, Casas S, Juanola X, et al. Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study. Clin Infect Dis. 2015;60:349–356.
   PubMed Web of Science ®Google Scholar
• Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs tuberculin skin test. Br J Dermatol. 2009;161:797–800.
   PubMed Web of Science ®Google Scholar
• Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2011;17:77–83.
   PubMed Web of Science ®Google Scholar
• Chang B, Park HY, Jeon K, et al. Interferon-gamma release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol. 2011;30:1535–1541.
   PubMed Web of Science ®Google Scholar
• Garcovich S, Ruggeri A, D’Agostino M, et al. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol. 2012;26:1572–1576.
   PubMed Web of Science ®Google Scholar
• Hsia EC, Cush JJ, Matteson EL, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res (Hoboken). 2013;65:309–313.
   PubMed Web of Science ®Google Scholar
• Andrews JR, Nemes E, Tameris M, et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respir Med. 2017;5:282–290.
   PubMed Web of Science ®Google Scholar
• Nemes E, Rozot V, Geldenhuys H, et al. Optimization and interpretation of serial QuantiFERON testing to measure acquisition of Mycobacterium tuberculosis infection. Am J Respir Crit Care Med. 2017;196:638–648.
   PubMed Web of Science ®Google Scholar
• Hatzara C, Hadziyannis E, Kandili A, et al. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis. 2015;74:1848–1853.
   PubMed Web of Science ®Google Scholar
• Ye H, Zhang XW, Mu R, et al. Anti-TNF therapy in patients with HBV infection: analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014;33:119–123.
   PubMed Web of Science ®Google Scholar
• Zhang MY, Zhu GQ, Zheng JN, et al. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. Expert Rev Anti Infect Ther. 2017;15:503–513.
   PubMed Web of Science ®Google Scholar
• Clarke WT, Amin SS, Papamichael K, et al. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation. Clin Immunol. 2018;191:59–62.
   PubMed Web of Science ®Google Scholar
• Harigai M, Koike R, Miyasaka N, et al. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357:1874–1876.
   PubMed Web of Science ®Google Scholar
• Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61:305–312.
   PubMed Web of Science ®Google Scholar
• Omer O, Cohen P, Neong SF, et al. Pneumocystis pneumonia complicating immunosuppressive therapy in Crohns disease: A preventable problem? Frontline Gastroenterol. 2016;7:222–226.
   PubMed Web of Science ®Google Scholar
• Podlipnik S, de la Mora L, Alsina M, et al. Pneumocystis jirovecii pneumonia in a patient with pustular psoriasis with an IL-36RN deficiency treated with infliximab: case report and review of the literature. Australas J Dermatol. 2017;58:e44–e47.
   PubMed Web of Science ®Google Scholar
• Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481–1484.
   PubMed Web of Science ®Google Scholar
• Mori S, Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51:2120–2130.
   PubMed Web of Science ®Google Scholar
• Friedman MA, Winthrop KL. Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist. Rheum Dis Clin North Am. 2017;43:1–13.
   PubMed Web of Science ®Google Scholar
• van Assen S, Elkayam O, Agmon-Levin N, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011;10:341–352.
   PubMed Web of Science ®Google Scholar
• Caso F, Ramonda R, Del Puente A, et al. Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-alpha therapy. Clin Exp Rheumatol. 2016;34:507–512.
   PubMed Web of Science ®Google Scholar
• Khan N, Shah Y, Trivedi C, et al. Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications. Aliment Pharmacol Ther. 2017;46:668–672.
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44–100.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–2293.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–2300.
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Carmona L, Ángel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57:756–761.
   PubMed Web of Science ®Google Scholar
• Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387:2312–2322.
   PubMed Web of Science ®Google Scholar
• Njie GJ, Morris SB, Woodruff RY, et al. Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Am J Prev Med. 2018 Jun 11. epub ahead of print. DOI:10.1016/j.amepre.2018.04.030.
   PubMed Web of Science ®Google Scholar
• Simkins J, Abbo LM, Camargo JF, et al. Twelve-week rifapentine plus isoniazid versus 9-month isoniazid for the treatment of latent tuberculosis in renal transplant candidates. Transplantation. 2017;101:1468–1472.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–2096.
   PubMed Web of Science ®Google Scholar